Evidence map›Paper›PMID 38581262›Full record

ArticleBritish journal of pharmacology2024

P2X

Simar Singh, Dennis Sarroza, Anthony English, Dale Whittington, Ao Dong, Michael Malamas, Alexandros Makriyannis, Mario van der Stelt, Yulong Li, Larry Zweifel and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The endocannabinoid 2-arachidonoylglycerol is released and transported on demand via extracellular microvesicles.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Simar SinghDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-5785-8292
Dennis SarrozaDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.
Anthony EnglishDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.
Dale WhittingtonDepartment of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.
Ao DongPeking University School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
Michael MalamasCenter for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA.
Alexandros MakriyannisCenter for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA.
Mario van der SteltLeiden Institute of Chemistry, Leiden University, Leiden, Netherlands.
Yulong LiPeking University School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
Larry ZweifelDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.
Michael R BruchasDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.
Benjamin B LandDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.
Nephi StellaDepartment of Pharmacology, University of Washington, Seattle, Washington, USA.
University of Washington · USNortheastern University · USPeking University · CNLeiden University · NL

Funding

University of Washington Center of Excellence in Opioid Addiction ResearchP30DA048736 · NIDA · UNIVERSITY OF WASHINGTON · PI Michael R. Bruchas · 2019 to 2026
$13.0M
Pharmacological Sciences SupplementT32GM007750 · NIGMS · UNIVERSITY OF WASHINGTON · PI ATKINS, WILLIAM M · 1985 to 2023
$12.6M
Novel fluorescent sensors for imaging neuromodulationU01NS113358 · NINDS · UNIVERSITY OF CALIFORNIA BERKELEY · PI DAN, YANG, LI, YULONG · 2019 to 2022
$4.3M
DISSECTING DYNORPHIN-KAPPA OPIOID MEDIATED REINSTATEMENT OF NICOTINE PREFERENCER37DA033396 · NIDA · WASHINGTON UNIVERSITY · PI Michael R. Bruchas · 2018 to 2026
$3.8M
DISSECTING DYNORPHIN-KAPPA OPIOID MEDIATED REINSTATEMENT OF NICOTINE PREFERENCER01DA033396 · NIDA · WASHINGTON UNIVERSITY · PI BRUCHAS, MICHAEL R. · 2013 to 2017
$1.9M
Molecular mechanism of ABHD6 enzymatic activity in neuronsR21NS118130 · NINDS · UNIVERSITY OF WASHINGTON · PI STELLA, NEPHI · 2020 to 2020
$428k
ABHD6 and amphetamine stimulated locomotionR21DA047626 · NIDA · UNIVERSITY OF WASHINGTON · PI STELLA, NEPHI, ZWEIFEL, LARRY S · 2019 to 2020
$409k
Dissecting PFC Endocannabinoid-THC -regulated circuits in movement behaviorF31DA055448 · NIDA · UNIVERSITY OF WASHINGTON · PI ENGLISH, ANTHONY EDWARD · 2022 to 2024
$131k
Beijing Municipal Science & Technology Commission Z181100001318002Beijing Municipal Science & Technology Commission Z181100001518004National Natural Science Foundation of China 31871087National Natural Science Foundation of China 31925017NIDA NIH HHS F31 DA055448NIDA NIH HHS P30 DA048736NIDA NIH HHS R01 DA033396NIDA NIH HHS R21 DA047626NIDA NIH HHS R37 DA033396NIGMS NIH HHS T32 GM007750NIH BRAIN Initiative 1U01NS113358NIH HHS DA033396NIH HHS DA047626NIH HHS DA055448NIH HHS NS118130NIH HHS T32GM007750NINDS NIH HHS R21 NS118130NINDS NIH HHS U01 NS113358Peking-Tsinghua Center for Life SciencesScience Fund for Creative Research Groups of the National Natural Science Foundation of China 81821092Shenzhen-Hong Kong Institute of Brain Science NYKFKT2019013State Key Laboratory of Membrane Biology at Peking University School of Life SciencesUniversity of Washington Center of Excellence in Opioid Addiction Research/Molecular Genetics Resource Core P30DA048736
6 · The paper itself

Abstract

background and purposeNeurotransmission and neuroinflammation are controlled by local increases in both extracellular ATP and the endocannabinoid 2-arachidonoyl glycerol (2-AG). While it is known that extracellular ATP stimulates 2-AG production in cells in culture, the dynamics and molecular mechanisms that underlie this response remain poorly understood. Detection of real-time changes in eCB levels with the genetically encoded sensor, GRAB EXPERIMENTAL APPROACH: 2-AG and arachidonoylethanolamide (AEA) levels in Neuro2a (N2a) cells were measured by LC-MS, and GRAB KEY

results2-AG and AEA increased GRAB CONCLUSIONS AND IMPLICATIONS: Considering that P2X

Indexed as

Arachidonic AcidsEndocannabinoidsGlyceridesNeuronsReceptors, Purinergic P2X7Adenosine TriphosphateAnimalsCell Line, TumorMiceMonoacylglycerol LipasesPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1ABHD6 protein, mouseAdenosine TriphosphateanandamideArachidonic AcidsEndocannabinoidsGlyceridesglyceryl 2-arachidonateMonoacylglycerol LipasesPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1Receptors, Purinergic P2X72‐AGATPendocannabinoidsgenetically encoded sensorpurinergic receptors

Identifiers

PMID38581262
PMCPMC11936313
OpenAlexW4394011109

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.